![]() |
|||||||
|
Fusion Protein:ZC3HAV1-BRAF |
Fusion Gene and Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: ZC3HAV1-BRAF | FusionPDB ID: 100608 | FusionGDB2.0 ID: 100608 | Hgene | Tgene | Gene symbol | ZC3HAV1 | BRAF | Gene ID | 56829 | 673 |
Gene name | zinc finger CCCH-type containing, antiviral 1 | B-Raf proto-oncogene, serine/threonine kinase | |
Synonyms | ARTD13|FLB6421|PARP13|ZAP|ZC3H2|ZC3HDC2 | B-RAF1|B-raf|BRAF1|NS7|RAFB1 | |
Cytomap | 7q34 | 7q34 | |
Type of gene | protein-coding | protein-coding | |
Description | zinc finger CCCH-type antiviral protein 1ADP-ribosyltransferase diphtheria toxin-like 13inactive Poly [ADP-ribose] polymerase 13zinc finger CCCH domain-containing protein 2zinc finger CCCH-type, antiviral 1 | serine/threonine-protein kinase B-raf94 kDa B-raf proteinB-Raf proto-oncogene serine/threonine-protein kinase (p94)B-Raf serine/threonine-proteinmurine sarcoma viral (v-raf) oncogene homolog B1proto-oncogene B-Rafv-raf murine sarcoma viral oncogene | |
Modification date | 20200313 | 20200329 | |
UniProtAcc | . | P15056 Main function of 5'-partner protein: FUNCTION: Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000305}. | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000242351, ENST00000464606, ENST00000471652, | ENST00000288602, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 7 X 7 X 6=294 | 48 X 58 X 16=44544 |
# samples | 8 | 69 | |
** MAII score | log2(8/294*10)=-1.877744249949 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(69/44544*10)=-6.0124909441832 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Fusion gene context | PubMed: ZC3HAV1 [Title/Abstract] AND BRAF [Title/Abstract] AND fusion [Title/Abstract] | ||
Fusion neoantigen context | PubMed: ZC3HAV1 [Title/Abstract] AND BRAF [Title/Abstract] AND neoantigen [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ZC3HAV1(138758602)-BRAF(140481493), # samples:3 | ||
Anticipated loss of major functional domain due to fusion event. | ZC3HAV1-BRAF seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ZC3HAV1-BRAF seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ZC3HAV1-BRAF seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ZC3HAV1-BRAF seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ZC3HAV1 | GO:0006471 | protein ADP-ribosylation | 25043379 |
Hgene | ZC3HAV1 | GO:0009615 | response to virus | 21876179 |
Hgene | ZC3HAV1 | GO:0045071 | negative regulation of viral genome replication | 21876179 |
Hgene | ZC3HAV1 | GO:0061014 | positive regulation of mRNA catabolic process | 21876179 |
Tgene | BRAF | GO:0000186 | activation of MAPKK activity | 29433126 |
Tgene | BRAF | GO:0006468 | protein phosphorylation | 17563371 |
Tgene | BRAF | GO:0010828 | positive regulation of glucose transmembrane transport | 23010278 |
Tgene | BRAF | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 19667065 |
Tgene | BRAF | GO:0043066 | negative regulation of apoptotic process | 19667065 |
Tgene | BRAF | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 22065586 |
Tgene | BRAF | GO:0071277 | cellular response to calcium ion | 18567582 |
Tgene | BRAF | GO:0090150 | establishment of protein localization to membrane | 23010278 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:138758602/chr7:140481493) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
Top |
Fusion Amino Acid Sequences |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000242351 | ZC3HAV1 | chr7 | 138758602 | - | ENST00000288602 | BRAF | chr7 | 140481493 | - | 3294 | 2189 | 236 | 3175 | 979 |
ENST00000464606 | ZC3HAV1 | chr7 | 138758602 | - | ENST00000288602 | BRAF | chr7 | 140481493 | - | 3366 | 2261 | 23 | 3247 | 1074 |
ENST00000471652 | ZC3HAV1 | chr7 | 138758602 | - | ENST00000288602 | BRAF | chr7 | 140481493 | - | 3365 | 2260 | 307 | 3246 | 979 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000242351 | ENST00000288602 | ZC3HAV1 | chr7 | 138758602 | - | BRAF | chr7 | 140481493 | - | 0.001133165 | 0.9988669 |
ENST00000464606 | ENST00000288602 | ZC3HAV1 | chr7 | 138758602 | - | BRAF | chr7 | 140481493 | - | 0.000791574 | 0.9992085 |
ENST00000471652 | ENST00000288602 | ZC3HAV1 | chr7 | 138758602 | - | BRAF | chr7 | 140481493 | - | 0.001167497 | 0.9988325 |
![]() |
Get the fusion protein sequences from here. |
Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for ZC3HAV1-BRAF |
![]() |
Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
ZC3HAV1 | chr7 | 138758602 | BRAF | chr7 | 140481493 | 2189 | 651 | KNESGTWIQYGEEKTLGRRDSSDDWE |
ZC3HAV1 | chr7 | 138758602 | BRAF | chr7 | 140481493 | 2260 | 651 | KNESGTWIQYGEEKTLGRRDSSDDWE |
ZC3HAV1 | chr7 | 138758602 | BRAF | chr7 | 140481493 | 2261 | 746 | KNESGTWIQYGEEKTLGRRDSSDDWE |
Top |
Potential FusionNeoAntigen Information of ZC3HAV1-BRAF in HLA I |
![]() |
ZC3HAV1-BRAF_138758602_140481493.msa |
![]() * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:01 | IQYGEEKTL | 0.9937 | 0.928 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B48:01 | IQYGEEKTL | 0.9787 | 0.7724 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B39:24 | IQYGEEKTL | 0.9324 | 0.872 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B14:01 | IQYGEEKTL | 0.8619 | 0.9447 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B14:02 | IQYGEEKTL | 0.8619 | 0.9447 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B39:01 | IQYGEEKTL | 0.8092 | 0.9866 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:03 | IQYGEEKTL | 0.7263 | 0.8923 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:10 | IQYGEEKTL | 0.6695 | 0.7425 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B39:13 | IQYGEEKTL | 0.6643 | 0.9923 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B38:01 | IQYGEEKTL | 0.6365 | 0.9931 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B13:02 | IQYGEEKTL | 0.6319 | 0.9085 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B38:02 | IQYGEEKTL | 0.6265 | 0.9934 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B13:01 | IQYGEEKTL | 0.5994 | 0.9881 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:37 | IQYGEEKTL | 0.5553 | 0.7988 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B47:01 | IQYGEEKTL | 0.4841 | 0.8129 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B52:01 | IQYGEEKTL | 0.0843 | 0.9895 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B48:01 | WIQYGEEKTL | 0.6509 | 0.8806 | 6 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B48:01 | TWIQYGEEKTL | 0.9892 | 0.908 | 5 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-C12:12 | IQYGEEKTL | 0.9779 | 0.9744 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:04 | IQYGEEKTL | 0.9702 | 0.9474 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-C06:03 | IQYGEEKTL | 0.9661 | 0.9955 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B48:03 | IQYGEEKTL | 0.8919 | 0.7478 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-A02:05 | IQYGEEKTL | 0.8205 | 0.5786 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B39:09 | IQYGEEKTL | 0.8153 | 0.9419 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B39:08 | IQYGEEKTL | 0.7444 | 0.9632 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B39:05 | IQYGEEKTL | 0.6273 | 0.9855 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:05 | IQYGEEKTL | 0.3023 | 0.9414 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B51:07 | IQYGEEKTL | 0.0607 | 0.9839 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B48:03 | WIQYGEEKTL | 0.3533 | 0.8116 | 6 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B48:03 | TWIQYGEEKTL | 0.8506 | 0.8166 | 5 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:27 | IQYGEEKTL | 0.9941 | 0.934 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:24 | IQYGEEKTL | 0.9939 | 0.9464 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:34 | IQYGEEKTL | 0.9937 | 0.928 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:33 | IQYGEEKTL | 0.9937 | 0.928 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:125 | IQYGEEKTL | 0.9937 | 0.928 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:50 | IQYGEEKTL | 0.9878 | 0.9462 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:53 | IQYGEEKTL | 0.9446 | 0.9146 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:73 | IQYGEEKTL | 0.9343 | 0.9788 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:68 | IQYGEEKTL | 0.9231 | 0.8063 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:12 | IQYGEEKTL | 0.9181 | 0.9454 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B40:12 | IQYGEEKTL | 0.8919 | 0.7478 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:30 | IQYGEEKTL | 0.8823 | 0.9447 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B39:02 | IQYGEEKTL | 0.8641 | 0.9921 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:54 | IQYGEEKTL | 0.8507 | 0.9055 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B39:31 | IQYGEEKTL | 0.8411 | 0.9862 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-C03:67 | IQYGEEKTL | 0.8303 | 0.9869 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B40:49 | IQYGEEKTL | 0.7735 | 0.7295 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-C06:08 | IQYGEEKTL | 0.7265 | 0.9922 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B40:21 | IQYGEEKTL | 0.7143 | 0.7864 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B39:11 | IQYGEEKTL | 0.6824 | 0.9491 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-A02:14 | IQYGEEKTL | 0.6443 | 0.7859 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B38:05 | IQYGEEKTL | 0.6365 | 0.9931 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B48:02 | IQYGEEKTL | 0.4441 | 0.9705 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:09 | IQYGEEKTL | 0.3346 | 0.922 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B35:28 | IQYGEEKTL | 0.3004 | 0.9753 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:20 | IQYGEEKTL | 0.2965 | 0.9682 | 7 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B15:30 | WIQYGEEKTL | 0.8762 | 0.9521 | 6 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B40:12 | WIQYGEEKTL | 0.3533 | 0.8116 | 6 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B40:21 | WIQYGEEKTL | 0.3503 | 0.8491 | 6 | 16 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | HLA-B40:12 | TWIQYGEEKTL | 0.8506 | 0.8166 | 5 | 16 |
Top |
Potential FusionNeoAntigen Information of ZC3HAV1-BRAF in HLA II |
![]() |
ZC3HAV1-BRAF_138758602_140481493.msa |
![]() * We used NetMHCIIpan v4.1 (%rank<0.5). |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | DRB1-0906 | GTWIQYGEEKTLGRR | 4 | 19 |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 | DRB1-0906 | SGTWIQYGEEKTLGR | 3 | 18 |
Top |
Fusion breakpoint peptide structures of ZC3HAV1-BRAF |
![]() * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
10480 | WIQYGEEKTLGRRD | ZC3HAV1 | BRAF | chr7 | 138758602 | chr7 | 140481493 | 2189 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ZC3HAV1-BRAF |
![]() * We used Glide to predict the interaction between HLAs and neoantigens. |
HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
HLA-B14:02 | 3BVN | 10480 | WIQYGEEKTLGRRD | -7.9962 | -8.1096 |
HLA-B14:02 | 3BVN | 10480 | WIQYGEEKTLGRRD | -5.70842 | -6.74372 |
HLA-B52:01 | 3W39 | 10480 | WIQYGEEKTLGRRD | -6.83737 | -6.95077 |
HLA-B52:01 | 3W39 | 10480 | WIQYGEEKTLGRRD | -4.4836 | -5.5189 |
HLA-A11:01 | 4UQ2 | 10480 | WIQYGEEKTLGRRD | -10.0067 | -10.1201 |
HLA-A11:01 | 4UQ2 | 10480 | WIQYGEEKTLGRRD | -9.03915 | -10.0745 |
HLA-A24:02 | 5HGA | 10480 | WIQYGEEKTLGRRD | -6.56204 | -6.67544 |
HLA-A24:02 | 5HGA | 10480 | WIQYGEEKTLGRRD | -5.42271 | -6.45801 |
HLA-B44:05 | 3DX8 | 10480 | WIQYGEEKTLGRRD | -7.85648 | -8.89178 |
HLA-B44:05 | 3DX8 | 10480 | WIQYGEEKTLGRRD | -5.3978 | -5.5112 |
HLA-A02:01 | 6TDR | 10480 | WIQYGEEKTLGRRD | -3.37154 | -4.40684 |
Top |
Vaccine Design for the FusionNeoAntigens of ZC3HAV1-BRAF |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 5 | 16 | TWIQYGEEKTL | ACATGGATTCAGTATGGAGAAGAGAAAACACTT |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 6 | 16 | WIQYGEEKTL | TGGATTCAGTATGGAGAAGAGAAAACACTT |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 7 | 16 | IQYGEEKTL | ATTCAGTATGGAGAAGAGAAAACACTT |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 3 | 18 | SGTWIQYGEEKTLGR | TCTGGCACATGGATTCAGTATGGAGAAGAGAAAACACTTGGTAGA |
ZC3HAV1-BRAF | chr7 | 138758602 | chr7 | 140481493 | 4 | 19 | GTWIQYGEEKTLGRR | GGCACATGGATTCAGTATGGAGAAGAGAAAACACTTGGTAGACGG |
Top |
Information of the samples that have these potential fusion neoantigens of ZC3HAV1-BRAF |
![]() |
Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
THCA | ZC3HAV1-BRAF | chr7 | 138758602 | ENST00000242351 | chr7 | 140481493 | ENST00000288602 | TCGA-KS-A4ID-01A |
Top |
Potential target of CAR-T therapy development for ZC3HAV1-BRAF |
![]() |
![]() * Minus value of BPloci means that the break point is located before the CDS. |
- In-frame and retained 'Transmembrane'. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
![]() * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to ZC3HAV1-BRAF |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to ZC3HAV1-BRAF |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | BRAF | C0025202 | melanoma | 24 | CGI;CTD_human;UNIPROT |
Tgene | BRAF | C1275081 | Cardio-facio-cutaneous syndrome | 14 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Tgene | BRAF | C0009402 | Colorectal Carcinoma | 8 | CTD_human;UNIPROT |
Tgene | BRAF | C0028326 | Noonan Syndrome | 8 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET |
Tgene | BRAF | C0238463 | Papillary thyroid carcinoma | 8 | CTD_human;ORPHANET |
Tgene | BRAF | C0040136 | Thyroid Neoplasm | 6 | CGI;CTD_human |
Tgene | BRAF | C0151468 | Thyroid Gland Follicular Adenoma | 6 | CTD_human |
Tgene | BRAF | C0175704 | LEOPARD Syndrome | 6 | CLINGEN;GENOMICS_ENGLAND |
Tgene | BRAF | C0549473 | Thyroid carcinoma | 6 | CGI;CTD_human |
Tgene | BRAF | C3150970 | NOONAN SYNDROME 7 | 5 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | BRAF | C0009404 | Colorectal Neoplasms | 4 | CTD_human |
Tgene | BRAF | C3150971 | LEOPARD SYNDROME 3 | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | BRAF | C1519086 | Pilomyxoid astrocytoma | 3 | ORPHANET |
Tgene | BRAF | C0004565 | Melanoma, B16 | 2 | CTD_human |
Tgene | BRAF | C0009075 | Melanoma, Cloudman S91 | 2 | CTD_human |
Tgene | BRAF | C0018598 | Melanoma, Harding-Passey | 2 | CTD_human |
Tgene | BRAF | C0023443 | Hairy Cell Leukemia | 2 | CGI;ORPHANET |
Tgene | BRAF | C0025205 | Melanoma, Experimental | 2 | CTD_human |
Tgene | BRAF | C0033578 | Prostatic Neoplasms | 2 | CTD_human |
Tgene | BRAF | C0152013 | Adenocarcinoma of lung (disorder) | 2 | CGI;CTD_human |
Tgene | BRAF | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human |
Tgene | BRAF | C0587248 | Costello syndrome (disorder) | 2 | CLINGEN;CTD_human |
Tgene | BRAF | C3501843 | Nonmedullary Thyroid Carcinoma | 2 | CTD_human |
Tgene | BRAF | C3501844 | Familial Nonmedullary Thyroid Cancer | 2 | CTD_human |
Tgene | BRAF | C0002448 | Ameloblastoma | 1 | CTD_human |
Tgene | BRAF | C0004114 | Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0010276 | Craniopharyngioma | 1 | CTD_human;ORPHANET |
Tgene | BRAF | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
Tgene | BRAF | C0017638 | Glioma | 1 | CGI;CTD_human |
Tgene | BRAF | C0019621 | Histiocytosis, Langerhans-Cell | 1 | CGI;ORPHANET |
Tgene | BRAF | C0022665 | Kidney Neoplasm | 1 | CTD_human |
Tgene | BRAF | C0023903 | Liver neoplasms | 1 | CTD_human |
Tgene | BRAF | C0024232 | Lymphatic Metastasis | 1 | CTD_human |
Tgene | BRAF | C0024694 | Mandibular Neoplasms | 1 | CTD_human |
Tgene | BRAF | C0027659 | Neoplasms, Experimental | 1 | CTD_human |
Tgene | BRAF | C0027962 | Melanocytic nevus | 1 | GENOMICS_ENGLAND |
Tgene | BRAF | C0036920 | Sezary Syndrome | 1 | CTD_human |
Tgene | BRAF | C0041409 | Turner Syndrome, Male | 1 | CTD_human |
Tgene | BRAF | C0079773 | Lymphoma, T-Cell, Cutaneous | 1 | CTD_human |
Tgene | BRAF | C0205768 | Subependymal Giant Cell Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0206686 | Adrenocortical carcinoma | 1 | CTD_human |
Tgene | BRAF | C0206754 | Neuroendocrine Tumors | 1 | CTD_human |
Tgene | BRAF | C0259783 | mixed gliomas | 1 | CTD_human |
Tgene | BRAF | C0278875 | Adult Craniopharyngioma | 1 | CTD_human |
Tgene | BRAF | C0280783 | Juvenile Pilocytic Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0280785 | Diffuse Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0334579 | Anaplastic astrocytoma | 1 | CGI;CTD_human |
Tgene | BRAF | C0334580 | Protoplasmic astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0334581 | Gemistocytic astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0334582 | Fibrillary Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0334583 | Pilocytic Astrocytoma | 1 | CGI;CTD_human |
Tgene | BRAF | C0338070 | Childhood Cerebral Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0345904 | Malignant neoplasm of liver | 1 | CTD_human |
Tgene | BRAF | C0376407 | Granulomatous Slack Skin | 1 | CTD_human |
Tgene | BRAF | C0406803 | Syringocystadenoma Papilliferum | 1 | GENOMICS_ENGLAND |
Tgene | BRAF | C0431128 | Papillary craniopharyngioma | 1 | CTD_human |
Tgene | BRAF | C0431129 | Adamantinous Craniopharyngioma | 1 | CTD_human |
Tgene | BRAF | C0547065 | Mixed oligoastrocytoma | 1 | CTD_human |
Tgene | BRAF | C0555198 | Malignant Glioma | 1 | CTD_human |
Tgene | BRAF | C0596263 | Carcinogenesis | 1 | CTD_human |
Tgene | BRAF | C0684249 | Carcinoma of lung | 1 | CGI;UNIPROT |
Tgene | BRAF | C0740457 | Malignant neoplasm of kidney | 1 | CTD_human |
Tgene | BRAF | C0750935 | Cerebral Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0750936 | Intracranial Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C0751061 | Craniopharyngioma, Child | 1 | CTD_human |
Tgene | BRAF | C0920269 | Microsatellite Instability | 1 | CTD_human |
Tgene | BRAF | C1527404 | Female Pseudo-Turner Syndrome | 1 | CTD_human |
Tgene | BRAF | C1704230 | Grade I Astrocytoma | 1 | CTD_human |
Tgene | BRAF | C1721098 | Replication Error Phenotype | 1 | CTD_human |
Tgene | BRAF | C2239176 | Liver carcinoma | 1 | CTD_human |
Tgene | BRAF | C4551484 | Leopard Syndrome 1 | 1 | GENOMICS_ENGLAND |
Tgene | BRAF | C4551602 | Noonan Syndrome 1 | 1 | CTD_human |
Tgene | BRAF | C4721532 | Lymphoma, Non-Hodgkin, Familial | 1 | UNIPROT |
Tgene | BRAF | C4733333 | familial non-medullary thyroid cancer | 1 | GENOMICS_ENGLAND |